

Niiaz Khasanov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6108957/niiaz-khasanov-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14
papers

6,225
citations

7
h-index

19
g-index

19
ext. papers

8,072
ext. citations

15.6
avg, IF

5.23
L-index

#	Paper	IF	Citations
14	Features of sinus rhythm restoration in patients with paroxysmal and persistent non-valvular atrial fibrillation and previous COVID-19 infection in iron-deficiency anaemia. <i>Kazan Medical Journal</i> , 2022 , 103, 54-62	0.2	
13	Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. <i>Russian Journal of Cardiology</i> , 2022 , 26, 4791	1.3	1
12	Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. <i>Russian Journal of Cardiology</i> , 2022 , 26, 4807	1.3	
11	Visit-to-visit blood pressure variability in patients after acute coronary syndrome. <i>Arterial Hypertension (Russian Federation)</i> , 2021 , 27, 206-215	0.7	
10	Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction. <i>Russian Journal of Cardiology</i> , 2020 , 25, 4049	1.3	0
9	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	40	106
8	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 618-628	18.1	120
7	Bleeding risk factors in patients with acute coronary syndrome: data from observational studies ORACUL II. <i>Russian Journal of Cardiology</i> , 2019 , 24, 7-16	1.3	4
6	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 380, 347-357	59.2	2455
5	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2	1277
4	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 1527-1539	59.2	390
3	GENETIC AND FUNCTIONAL FACTORS IN THE DEVELOPMENT OF COGNITIVE IMPAIRMENT IN HYPERTENSION: A PROSPECTIVE STUDY. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2016 , 8, 14-20	0.7	2
2	Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. <i>Journal of Hypertension</i> , 2016 , 34, 139-48	1.9	8
1	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2013 , 369, 1327-35	59.2	1858